Bristol-Myers Squibb Company (BMS) announced Tuesday that it had signed an agreement to acquire biopharmaceutical company ZymoGenetics for approximately $885 million, or $9.75 per share in cash.
Vertex Announces Positive Phase III Data for Hepatitis Drug
The New York Times reports that about 75 percent of patients taking telaprevir in combination with existing hepatitis C drugs were essentially cured of the virus, compared to 44 percent on standard therapy alone.
The Universal Vaccines of Inovio Biomedical
Inovio is developing a universal flu vaccine engineered to prevent several strains of influenza at once.
Vertex to Sell 1.5 Million Shares
Vertex Pharmaceuticals has been busy raising cash to prepare for the launch of telaprevir to treat hepatitis C.
Potential Hepatitis C Breakthrough for Santaris
In preliminary testing done on chimpanzees chronically infected with the hepatitis C virus, SPC3649 dramatically reduced virus levels with no toxic side effects.
